Treatment of Moraxella catarrhalis Pneumonia in Adult Inpatients with Severe Community-Acquired Pneumonia
Clinical Scenario
This protocol covers adult patients hospitalised with severe community-acquired pneumonia (CAP) due to Moraxella catarrhalis, in whom risk factors for MRSA or Pseudomonas aeruginosa are absent.
Treatment Approach
Empiric management is based on combination antibiotic therapy built around a beta-lactam agent — the full regimen, agent selection, and step-down criteria are available in the structured protocol.
Treatment Goals
The clinical endpoint is stability, defined as resolution of:
- Vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, temperature)
- Ability to eat
- Normal mentation
Most patients achieve clinical stability within the first 48 to 72 hours.
References
DOI: 10.1164/rccm.201908-1581ST
- In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
- a β-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or
- a β-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
- A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation.
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗